Therefore, mARC1 is increasingly attractive as a potential target for enzyme inhibition for the mediation of fatty liver disease and obesity—how these systems are modulated during gestation and placentation however, and their influence on gestational complications, are currently unexplored. This evidence concerns the gene MTARC1 and fatty liver disease.